We’re proud to share that our clinical validation study, published earlier this year in Breast Cancer Research and Treatment, has been recognised as one of the journal’s top-performing articles, ranked in the 97th percentile for popularity.
The study highlights ground-breaking findings:
The study reports the prognostic performance of Digistain® for risk classification in HR+, HER2- breast cancer.
Dive into the details of our study and findings here:
Digistain has been nominated for the EIT Awards 2026 in the Venture Award category. The Venture Award recognises organisations combining strong commercial potential with meaningful
In September 2026 Sasha Becejac, Digistain’s CCO, was invited to speak at On Targeted Molecular Oncology 2026 in Ankara, Türkiye, sharing the latest developments around
In September 2026 Sarah Bond, our COO for the MENA region, took part in The Future Health Dialogue roundtable hosted at Hub71 in Abu Dhabi,
Supported by:
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.